Stock listing

Dusseldorf:8CC Cocrystal Pharma, Inc. Aktie

German listing (Dusseldorf) of Cocrystal Pharma, Inc. · home listing NASDAQ:COCP

Follow Cocrystal Pharma, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:COCP

$1.02 USD -0.01 (-1.0%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:COCP

Since Jul 6, 2026 -1.9% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$1.01 – $1.06 USDOct 16, 2026
Volume
22,775 sharesOct 16, 2026
Market value
$19.65M USDAt the close on Oct 16, 2026 · price × 19.26M shares outstanding
Cocrystal Pharma, Inc. logo
Ticker
Dusseldorf:8CC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Dusseldorf
Currency
EUR

What changed lately

Latest news

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Sep 9, 2026

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Aug 17, 2026

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Aug 3, 2026

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

Jun 3, 2026

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

May 26, 2026

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

May 15, 2026

COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention

Apr 7, 2026

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

Apr 2, 2026

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Mar 31, 2026

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

Mar 9, 2026

All Cocrystal Pharma, Inc. news

Financings

  • Private placement of common stock

    Aug 3, 2026

    Closed: US$5M raised · US$0.9134 a share

    Buyers: OPKO (5,474,053 shares of common stock for $5.0 million)

    Closed Aug 3, 2026

Read by 6ix AI from the company's releases

Decks

Cocrystal Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 152 in all · newest Sep 9, 2026 · oldest 2019
Decks
29 decks · latest Apr 30, 2026

Where Cocrystal Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:COCP · Home listingNASDAQUnited StatesUSD
Tradegate:8CCTradegateGermanyEUR
Lang & Schwarz:A3DWYXLang & SchwarzGermanyEUR
LS Exchange:A3DWYXLS ExchangeGermanyEUR
gettex:8CCgettexGermanyEUR
BOATS:COCPBOATSUnited StatesUSD
Dusseldorf:8CC · This pageDusseldorfGermanyEUR
Frankfurt:8CCFrankfurtGermanyEUR
Munich:8CCMunichGermanyEUR
Stuttgart:8CCStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Cocrystal Pharma, Inc.